Novo Nordisk and Orbis Medicines Sign Up-to-$1.4 Billion Oral Macrocyclic Peptide Pact for Cardiometabolic Disease

Key takeaways

• Novo Nordisk and Orbis Medicines have entered a multi-target discovery and licensing collaboration worth up to $1.4 billion, according to a Reuters report dated 17 September 2026.
• The pact will use Orbis's AI-enabled nGen platform to discover oral macrocyclic peptides for cardiometabolic diseases presently treated with injectable drugs.
• Novo will make a separate strategic equity investment in privately held Orbis; neither figure has been disclosed.
• Orbis has reported preclinical oral bioavailability of up to 18% for its synthetic macrocycles — a class that sits structurally between small molecules and biologics.
• The collaboration arrives as the macrocyclic peptide sector more broadly attracts multi-billion-dollar capital flows, with Novartis, AstraZeneca, and sovereign wealth funds all backing competing platforms.

The deal in brief

Reuters reported on 17 September 2026 that Orbis Medicines signed a multi-target discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases traditionally treated with injectable drugs. The pact includes upfront and milestone payments plus tiered royalties on future product sales. Novo will also make a strategic investment in privately held Orbis, though both sides declined to disclose the investment size or how the $1.4 billion is apportioned.

The collaboration will use Orbis's AI-enabled nGen platform to discover macrocycles — ring-shaped molecules that Orbis says can reach targets that are hard for conventional small molecules. No development candidate, indication, or first-in-human date was disclosed at this stage.

What macrocyclic peptides are and why they matter

Macrocyclic peptides are ring-closed amino-acid sequences that occupy a chemical space between small molecules and large biologics. Their cyclic geometry confers conformational rigidity, which typically improves binding affinity and metabolic stability relative to linear peptides. Macrocyclic peptides have been described as a "goldilocks" drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways.

The practical challenge — and the reason the class has attracted sustained investment in AI-driven platforms — is that identifying macrocycles with adequate oral bioavailability has historically been difficult. Unnatural Products, a California-based competitor in the space, reasons that macrocyclic peptides offer an effective new class of therapeutics that combine the selectivity and potency of biologics with the flexibility and drug-like properties of small molecules. UNP describes its platform as an integrated discovery engine that rapidly generates potent and selective oral and injectable macrocycles by joining AI-guided molecular design, massively parallel synthesis, and direct-to-biology screening.

For Orbis, the headline preclinical figure is notable: Graugaard, speaking to Reuters, said synthetic macrocycles had achieved up to 18% oral bioavailability in preclinical studies. That figure is not a clinical readout and should be treated with appropriate caution until confirmed in human pharmacokinetic data, but it is meaningfully higher than the single-digit oral bioavailability typically associated with unmodified linear peptides.

Strategic rationale for Novo Nordisk

Novo Nordisk's interest in oral delivery is well established. Novo said the work builds on SNAC, the oral peptide absorption technology it acquired with Emisphere Technologies in 2020, which underpins its oral GLP-1 medicines. Oral semaglutide (Rybelsus) and the recently launched oral Wegovy pill both rely on SNAC to overcome the gastrointestinal barrier; the Orbis collaboration represents an adjacent but structurally distinct bet — macrocyclic chemistry rather than formulation technology — to expand the range of targets accessible by mouth.

Orbis said the multi-target collaboration will hunt oral macrocycle drugs for cardiometabolic disease. Graugaard called it a chance to show AI-enabled macrocycle discovery in a disease class now dominated by injectables.

The deal also fits Novo's competitive positioning. Novo Nordisk submitted CagriSema to the US FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials, with a decision anticipated by late 2026. The company stated that CagriSema did not meet the primary endpoint of non-inferiority to tirzepatide for weight loss in the REDEFINE 4 head-to-head trial, where tirzepatide produced greater mean weight loss at 84 weeks. Against that backdrop, extending the pipeline into differentiated oral macrocycle assets reduces Novo's dependence on a single mechanistic axis.

Sector context: capital is concentrating in macrocyclic platforms

The Orbis agreement arrives as a cluster of significant transactions has formed around the macrocyclic peptide modality in 2026.

Peptide drug discovery company Syneron Bio closed a $150 million Series B round to support its macrocyclic peptide development platform. After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million the previous year, the Beijing-based company used the latest round to accelerate its AI-driven Synova platform. Additional investors in that round included a wholly owned subsidiary of the Abu Dhabi Investment Authority, True Light Capital (a Temasek subsidiary), Qiming Venture Partners, and BioTrack Capital, with existing shareholders including AstraZeneca continuing their support.

Separately, Novartis in February 2026 inked a deal potentially worth more than $1.7 billion with California-based Unnatural Products to develop macrocyclic peptides. Unnatural Products itself closed a $45 million Series B in March 2026, led by The Venture Collective with participation from argenx, Merck Global Health Innovation Fund, and others.

Across the sector, the AI-driven peptide drug discovery platform market was valued at approximately USD 1.21 billion in 2026, having grown from USD 1.08 billion in 2025, and is projected to expand at a compound annual growth rate of approximately 12.3%, reaching USD 2.44 billion by 2032.

Implications for research procurement

For UK and European laboratory buyers, the acceleration of macrocyclic peptide platforms has several practical consequences:

Reference standard demand. As clinical programmes advance from AI-generated hits toward in-vivo validation, demand for analytically characterised macrocyclic reference standards will increase. Procurement teams should anticipate tighter availability windows for custom macrocycle synthesis services, particularly from CDMOs that are simultaneously scaling commercial GLP-1 API capacity.

Developability integration. One of the most practically impactful shifts in peptide drug discovery is the migration of developability assessment upstream into hit identification. Permeability, metabolic stability, and aggregation propensity are entering primary or early secondary screening cascades, particularly in programmes directed toward macrocyclic peptides and intracellular targets. The rationale is straightforward: developability failures identified at later stages are expensive and largely avoidable. Integrating CMC thinking at hit identification aligns discovery output with real development requirements and reduces programme timelines at their most vulnerable point.

Platform partnerships as a supply-chain signal. The concentration of macrocyclic peptide discovery in AI-platform companies that have signed pharma partnerships (Orbis with Novo, Syneron with AstraZeneca, UNP with Novartis) means the asset pipeline is increasingly proprietary. Research organisations seeking access to novel macrocyclic sequences for exploratory studies will likely need to engage through formal licensing or sponsored-research arrangements rather than via open-market procurement.

What remains unknown

The Novo–Orbis collaboration is, as announced, a discovery-stage agreement. No clinical candidate has been named, no indication has been confirmed, and no IND or CTA filing has been disclosed. The $1.4 billion headline figure represents the maximum potential value of milestones across multiple programmes, not committed capital. Preclinical bioavailability data in animals does not reliably predict human pharmacokinetic performance for macrocyclic peptides, where species differences in intestinal transporters and metabolic enzymes are pronounced. Research teams should treat the disclosed 18% oral bioavailability figure as a preclinical signal, not a clinical benchmark.

Sources: Reuters, 17 September 2026 — Novo-Orbis deal; FierceBiotech — Syneron Bio Series B; BioSpace — Syneron Bio Series B press release; GEN — Novartis/UNP macrocyclic peptide partnership; CBInsights/Unnatural Products — Series B; IRBM — Peptide drug discovery in 2026; Research and Markets — AI peptide platform market; Clinical Trials Arena — CagriSema tirzepatide head-to-head